CRISPR Therapeutics AG
AI Executive Summary
AI-powered analysis of 10-Q filing content
CRISPR Therapeutics shows mixed signals with improved operating performance but deteriorating financial position. Net loss decreased 10% year-over-year to $122.9M, and operating expenses fell 12% to $131.7M, indicating better cost management. However, the company took on $585.5M in new long-term debt during Q1 2026, signaling potential funding pressures despite strong cash reserves of $2.4B.
Red Flags Detected (4)
New long-term debt of $585.5M added in Q1 2026 vs $0 in prior period
Accumulated deficit increased to $2.07B from $1.95B in one quarter
Revenue remains minimal at only $1.5M vs substantial operating expenses of $131.7M
1 more red flag detected
Key Takeaways
Strong liquidity position with $2.4B in current assets provides substantial runway
Operating performance improving with 10% reduction in net loss year-over-year
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.